Authors
Natalia B Mikhailova, Maria I Kislova, Maria O Ivanova, Julia A Zhuravleva, Elena A Dmitrieva, Elena V Kondakova, Anna G Smirnova, Yana V Krylova, Olga V Kudyasheva, Yulia Y Vlasova, Anastasya V Beynarovich, Nikita P Volkov, Ivan S Moiseev, Eugene A Nikitin, Alexander D Kulagin
Published in
Hematological oncology. Volume 44. Issue 5. Pages e70229.
Abstract
The role of allogeneic hematopoietic cell transplantation (alloSCT) in chronic lymphocytic leukemia (CLL) has decreased in recent years due to the emergence of new effective targeted agents for the treatment of this disease. However, for a certain group of heavily pretreated or high-risk CLL patients with no other therapeutic options, allo-SCT remains important. Due to the fact that in most high-risk CLL patients it is possible to achieve durable response as a result of Bruton's tyrosine kinase inhibitors (ВТК), BCL-2 inhibitor and especially in their combined application, including in the first line of therapy, the choice of time point for alloSCT becomes relevant. In this retrospective study allo-SCT was performed in 44 patients with the period from 2006 to 2023. Progression-free survival was 79.2% at 12 months and 69.3% at 24 months. Similarly, overall survival was 81.4% at 12 months and 74% at 24 months. Graft-versus-host disease relapse-free survival was 57%. Despite small sample size, our study demonstrates that alloSCT has become a significantly safer procedure in patients with CLL.
PMID:
42572462
Bibliographic data and abstract were imported from PubMed on 10 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0